<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00217308</url>
  </required_header>
  <id_info>
    <org_study_id>04-0169-A</org_study_id>
    <nct_id>NCT00217308</nct_id>
  </id_info>
  <brief_title>Effect of Probiotic Lactobacilli on Vaginal Flora of Pregnant Women at High Risk for Preterm Delivery</brief_title>
  <official_title>Effect of Probiotic Lactobacilli on Vaginal Flora of Pregnant Women at High Risk for Preterm Delivery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mount Sinai Hospital, Canada</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mount Sinai Hospital, Canada</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose of the study is to determine the effect of probiotic lactobacilli on the vaginal&#xD;
      flora and cytokine profile during pregnancy, and the incidence of preterm labour in women at&#xD;
      high risk for preterm birth.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Preterm labour involves multiple causes - one of the most significant factors being a prior&#xD;
      history of preterm birth. Infection is another major cause of preterm labour (PTL) and is&#xD;
      estimated to cause up to 30% of PTL. Bacterial Vaginosis (BV) is an alteration in the&#xD;
      endogenous vaginal microflora preceded by a decreased presence of Lactobacilli species and&#xD;
      increased growth of gardnerella and other pathogens. BV is a strong risk factor for PTL, and&#xD;
      is associated with a 40% increased risk in some populations. Initial studies suggested that&#xD;
      the treatment of BV with antibiotics could decrease the incidence of PTL, but this has not&#xD;
      been confirmed by randomized trials. There is substantial evidence that the &quot;normal&quot;&#xD;
      lactobacillus dominated urogenital microflora play an important role in maintenance of a&#xD;
      healthy urinary and reproductive tract.&#xD;
&#xD;
      One hundred and sixty (160) women at high risk for PTL, based on a prior history of preterm&#xD;
      birth, will be approached at their first antenatal visit to participate. Recruitment of 54&#xD;
      patients with symptomatic or asymptomatic BV (based on Nugent Scoring). Women with documented&#xD;
      BV will be randomized to either treatment with lactobacilli preparation (n=27) or placebo&#xD;
      (n=27). Women with symptomatic BV will be treated with oral Metronidazole prior to starting&#xD;
      the lactobacilli or placebo. None of the subjects, researchers or clinical staff will know&#xD;
      which preparation each woman receives.&#xD;
&#xD;
      This study will be the first to examine the ability of lactobacilli preparations to maintain&#xD;
      a normal vaginal flora in pregnant women. In addition, the results will potentially serve as&#xD;
      the basis for a multi-centre RCT to determine efficacy of this treatment in preventing&#xD;
      preterm birth.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Tightly defined inclusion criteria were making recruitment very slow.&#xD;
  </why_stopped>
  <start_date type="Actual">February 2005</start_date>
  <completion_date type="Actual">September 2007</completion_date>
  <primary_completion_date type="Anticipated">July 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determination if restoration of a normal vaginal flora through the use of probiotics reduces the incidence of PTB.</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Premature Birth</condition>
  <condition>Bacterial Vaginosis</condition>
  <arm_group>
    <arm_group_label>Lactobacillus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo capsules</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lactobacilli GR-1 and RC-14</intervention_name>
    <description>Probiotic Lactobacilli will be compared to placebo</description>
    <arm_group_label>Lactobacillus</arm_group_label>
    <arm_group_label>Placebo capsules</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  pregnant women with previous incidence of preterm labour&#xD;
&#xD;
          -  otherwise healthy&#xD;
&#xD;
          -  over 18 years of age&#xD;
&#xD;
          -  able to provide informed consent&#xD;
&#xD;
          -  less than or equal to 16 weeks gestation&#xD;
&#xD;
          -  singleton pregnancy&#xD;
&#xD;
          -  normal uterine cavity&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  significant medical complications (preeclampsia, thrombophilia, hypertension)&#xD;
&#xD;
          -  multiple pregnancy&#xD;
&#xD;
          -  less than 18 years of age&#xD;
&#xD;
          -  patients receiving antibiotics or other antimicrobial therapies at time of recruitment&#xD;
&#xD;
          -  fetal complications such as intrauterine growth restriction or other abnormalities&#xD;
&#xD;
          -  diabetes&#xD;
&#xD;
          -  documented need for cervical cerclage&#xD;
&#xD;
          -  patient enrolled in other clinical trials&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alan Bocking, MD, FRCSC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chief, Department of Obstetrics and Gynaecology, Mount Sinai Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <study_first_submitted>September 14, 2005</study_first_submitted>
  <study_first_submitted_qc>September 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <last_update_submitted>August 29, 2017</last_update_submitted>
  <last_update_submitted_qc>August 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mount Sinai Hospital, Canada</investigator_affiliation>
    <investigator_full_name>Alan Bocking</investigator_full_name>
    <investigator_title>Clinician Scientist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaginosis, Bacterial</mesh_term>
    <mesh_term>Premature Birth</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

